CLYM
Climb BioBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
CLYM vs peer average
61/100
CLYM vs. peer average (B vs. C)
Grade spread
A 3 · B 1 · C 3 · F 2
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
VERA is the first available peer comparator.
Vera is a pathway comparator for CLYM116 because Climb's 10-K names atacicept among BAFF/APRIL competitors, but it is not a direct same-stage peer and mainly serves as an advanced benchmark for how far ahead the APRIL field already is [#10-K-2026-03-05].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
CLYM
Climb Bio
VERA
Vera Therapeutics
Grade
B
C
Momentum
97
18
Value
41
41
Sentiment
27
100
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Mixed
Grade position vs VERA
CLYM / VERA
Grade Position
In line
CLYM vs. peer average (B vs. C)
61/100
Momentum
97
CLYMValue
41
CLYMSentiment
27
VERARotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs CLYM
VERA is the first peer returned for this comparison set.